Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE These results suggest that, in contrast to the by far most frequently occurring E2(Arg158----Cys) allele, heterozygosity for this uncommon E2 allele may cause familial dysbetalipoproteinemia. 3690877

1987

dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia. 24953047

2014

dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity. 17593519

2007

dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE This explains the significant effect of the apoE gene locus on the variability of plasma lipoprotein concentrations and moreover the implication of apoE alleles in the aetiology of multifactorial forms of hyperlipidaemia e.g. familial type III hyperlipidaemia (apoE2; arg158----cys) and polygenic hypercholesterolaemia (apoE4; cys112----arg). 3141688

1988

dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE However, apoE2(Arg158-->Cys) displayed more activity than the variants associated with the dominant forms of type III hyperlipoproteinemia. 8175773

1994

dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE ApoE2 which differs from apoE3 by the single amino acid substitution Arg158Cys located near the LDLR recognition site exhibits impaired binding to the receptor and an inability to promote clearance of TG-rich lipoprotein remnant particles; this isoform is associated with Type-III hyperlipoproteinemia. 25328986

2014

dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE Type III hyperlipoproteinaemia (HLP) is usually associated with homozygosity for apolipoprotein (apo) E2 (arg-158-->Cys). 8682150

1996

dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE We propose that the single base deletion in the apo E gene which is the cause of a non-functional 'null' allele in addition to a probably dominant apo E1 (Gly127-->Asp, Arg158-->Cys) variant of late or incomplete penetrance are the primary genetic defects in this kindred leading to severe dysbetalipoproteinemia. 1360898

1992

dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE We conclude that FD is a genetically heterogeneous disease entity, displaying a recessive mode of inheritance with strongly reduced penetrance in case of the common E2(arg158----cys) variant and with a dominant mode of inheritance with high penetrance in case of the rare E2(lys146----gln) mutant. 2313204

1990

dbSNP: rs11542041
rs11542041
0.100 GeneticVariation BEFREE In all studied populations the receptor-binding defective apo E2 (arg158----cys) is associated with low cholesterol and apo B in heterozygotes and results in primary dysbetalipoproteinemia or type III hyperlipoproteinemia in homozygotes. 3544759

1987

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE We described the mutation apo E2* (Arg136 --> Cys) in a family with elevated lipid levels, but there was no confirmation of the connection between this mutation and type III hyperlipoproteinemia or hyperlipoproteinemia at all. 11043917

2000

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE In comparison, beta-VLDL+apoE(Arg142-->Cys), beta-VLDL+apoE(Arg145-->Cys), and beta-VLDL+apoE-Leiden, which are associated with dominant type III hyperlipoproteinemia, bound more poorly. 8175773

1994

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE Apolipoprotein E-4Philadelphia (Glu13----Lys,Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. 1674745

1991

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. 9157949

1997

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE In an initiated study of Qataris, we observed that 17% of the African-derived genetic subgroup were heterozygotes for a rare Arg145Cys (R145C) variant that functions as a dominant trait with incomplete penetrance associated with type III hyperlipoproteinemia. 24239320

2014

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia. 1352296

1992

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia. 8682150

1996

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE As the dominant apoE variants known so far are characterized by more pronounced reductions of heparin binding, we suggest that apoE2 (Arg136 --> Cys) is not associated with dominant expression of type III hyperlipoproteinemia. 9548597

1998

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE Restriction isotyping of apolipoprotein E R145C in type III hyperlipoproteinemia. 7735921

1995

dbSNP: rs573658040
rs573658040
0.100 GeneticVariation BEFREE This finding supports the notion that although apoE 2*(Arg136-->Cys) mutation is perhaps not sufficient to cause FD itself, the presence of other genetic and/or environmental factors can lead to the phenotypic expression of the disease in the carriers. 14535841

2003

dbSNP: rs11542037
rs11542037
0.010 GeneticVariation BEFREE Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia. 8830931

1996

dbSNP: rs1466963971
rs1466963971
0.010 GeneticVariation BEFREE Identification of a new apolipoprotein E variant (E2 Arg142-->Leu) in type III hyperlipidemia. 7772063

1995

dbSNP: rs199768005
rs199768005
0.010 GeneticVariation BEFREE None of the family members carrying APOE*3-(Cys-112-->Arg; Arg-251-->Gly) and/or APOE*2(Val-236-->Glu) exhibited lipoprotein abnormalities characteristic of familial dysbetalipoproteinaemia, although three family members carrying APOE*3-(Cys-112-->Arg; Arg-251-->Gly) showed hypertriglyceridaemia. 8156744

1994

dbSNP: rs267606661
rs267606661
0.010 GeneticVariation BEFREE None of the family members carrying APOE*3-(Cys-112-->Arg; Arg-251-->Gly) and/or APOE*2(Val-236-->Glu) exhibited lipoprotein abnormalities characteristic of familial dysbetalipoproteinaemia, although three family members carrying APOE*3-(Cys-112-->Arg; Arg-251-->Gly) showed hypertriglyceridaemia. 8156744

1994

dbSNP: rs267606664
rs267606664
0.010 GeneticVariation BEFREE We propose that the single base deletion in the apo E gene which is the cause of a non-functional 'null' allele in addition to a probably dominant apo E1 (Gly127-->Asp, Arg158-->Cys) variant of late or incomplete penetrance are the primary genetic defects in this kindred leading to severe dysbetalipoproteinemia. 1360898

1992